Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $884,392 - $970,425
22,700 Added 38.87%
81,100 $3.32 Million
Q1 2024

May 15, 2024

SELL
$40.88 - $43.27 $1.02 Million - $1.08 Million
-25,000 Reduced 29.98%
58,400 $2.47 Million
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $1.22 Million - $2.55 Million
60,100 Added 257.94%
83,400 $3.54 Million
Q3 2023

Nov 14, 2023

SELL
$20.26 - $31.91 $514,604 - $810,514
-25,400 Reduced 52.16%
23,300 $508,000
Q2 2023

Aug 14, 2023

BUY
$23.9 - $35.38 $592,720 - $877,424
24,800 Added 103.77%
48,700 $1.55 Million
Q1 2023

May 15, 2023

SELL
$22.82 - $35.32 $285,250 - $441,500
-12,500 Reduced 34.34%
23,900 $582,000
Q4 2022

Feb 14, 2023

BUY
$25.35 - $31.96 $98,865 - $124,644
3,900 Added 12.0%
36,400 $1.15 Million
Q3 2022

Nov 14, 2022

BUY
$25.5 - $41.42 $280,500 - $455,620
11,000 Added 51.16%
32,500 $918,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.